Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
Neuro Oncol. 2024 Jul 5;26(7):1181-1194. doi: 10.1093/neuonc/noae049.
Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
脑肿瘤的诊断随着正电子发射断层扫描(PET)和先进的磁共振成像(MRI)技术的应用而有了显著的发展。除了解剖学 MRI,这些方式还可能为一些临床应用提供有价值的信息,如鉴别诊断、肿瘤范围的划定、预后、区分肿瘤复发与治疗相关的变化,以及对抗癌治疗反应的评估。特别是,神经肿瘤学反应评估(RANO)小组、欧洲神经肿瘤学会以及主要的欧洲和美国核医学学会的联合建议强调,与单独的解剖学 MRI 相比,放射性标记氨基酸的额外临床价值是显著的,应支持其广泛的临床应用。对于先进的 MRI 及其在临床实践中的不断增加的应用,“启动脑肿瘤药物开发联盟标准化小组委员会”最近提供了一个广泛使用的动态对比磁共振灌注成像的更新采集协议。除了氨基酸 PET 和灌注 MRI,其他 PET 示踪剂和先进的 MRI 技术(如磁共振波谱)具有相当大的临床兴趣,并越来越多地被整合到日常临床实践中。然而,这些方式存在一些缺点,在临床常规中应该考虑到这些缺点。本综述全面介绍了在脑胶质瘤或脑转移瘤患者中进行 PET 成像和先进 MRI 技术可能存在的挑战、局限性和缺陷。尽管存在这些问题,PET 成像和先进 MRI 技术在脑肿瘤管理中仍然发挥着不可或缺的作用。通过跨学科合作、标准化协议和不断创新来认识和减轻这些挑战,将进一步提高这些方式在指导最佳患者护理方面的效用。